CCX354: Phase II data

The double-blind, international Phase II CARAT-2 trial in 160 patients showed that once-daily 200 mg oral CCX354 met the secondary endpoint of significantly improving ACR20 response rate at week 12 vs. placebo (56% vs. 30%, p=0.014). The twice-daily 100 mg dose of CCX354 led to an ACR20 response rate of 44% (p-value undisclosed). ChemoCentryx did not say whether the 100 mg dose met the endpoint. Once-daily 200 mg CCX354 also significantly reduced levels of CRP from baseline to week 12 vs. placebo (p=0.023). The company also said that reductions in 3 biomarkers of bone turnover - C-terminal telopeptide (CTX), procollagen type I N-propeptide (PINP) and osteocalcin - were more pronounced in patients treated with CCX354 compared to placebo. CCX354 was well tolerated. ...